Biopharma Daily Updates - 12/22/20

XBI $151.13 (+0.8%) 📈


COVID:

$CYDY (-12%) - FDA Resumes eIND Approval for Severe-to-Critical COVID-19 Patients Use of Vyrologix™ (leronlimab) Following Full Enrollment in CytoDyn’s Phase 3 Trial

https://www.cytodyn.com/newsroom/press-releases/detail/492/fda-resumes-eind-approval-for-severe-to-critical-covid-19


$KNSA (-0.2%) - Kiniksa Announces Data from U.S. Investigator-Initiated Study of Mavrilimumab in Severe COVID-19 Pneumonia and Hyperinflammation

https://investors.kiniksa.com/news-releases/news-release-details/kiniksa-announces-data-us-investigator-initiated-study


$RDHL (+0.1%) - RedHill's Phase 2/3 COVID-19 Study of Opaganib Passes Second DSMB with Unanimous Recommendation to Continue

https://ir.redhillbio.com/news-releases/news-release-details/redhills-phase-23-covid-19-study-opaganib-passes-second-dsmb



PIPELINE:

$VYGR (+3%) - Voyager Therapeutics Provides Update On NBIb-1817 (VY-AADC) Gene Therapy Program

https://ir.voyagertherapeutics.com/news-releases/news-release-details/voyager-therapeutics-provides-update-nbib-1817-vy-aadc-gene


$SPPI (-3%) - Spectrum Provides Poziotinib Update after Successful Pre-NDA Meeting with the FDA

https://investor.sppirx.com/news-releases/news-release-details/spectrum-provides-poziotinib-update-after-successful-pre-nda


$BCRX (-8.5%) - BioCryst Provides Update on Galidesivir Program

https://ir.biocryst.com/news-releases/news-release-details/biocryst-provides-update-galidesivir-program


$NKTR (+0.4%) - Nektar Therapeutics Announces Agreement with Healthcare Royalty to Sell ADYNOVATE® and MOVANTIK® Royalties for $150 Million

https://ir.nektar.com/news-releases/news-release-details/nektar-therapeutics-announces-agreement-healthcare-royalty-sell


$OCUL (+5%) - Ocular Therapeutix™ Announces Submission to the FDA of a Supplemental New Drug Application for DEXTENZA® (dexamethasone ophthalmic insert) for the Treatment of Ocular Itching Associated with Allergic Conjunctivitis

http://investors.ocutx.com/news-releases/news-release-details/ocular-therapeutixtm-announces-submission-fda-supplemental-new


$RYTM (-4.5%) - Rhythm Pharmaceuticals Announces Positive Topline Results from Pivotal Phase 3 Clinical Trial Evaluating Setmelanotide in Bardet-Biedl and Alström Syndromes

https://ir.rhythmtx.com/news-releases/news-release-details/rhythm-pharmaceuticals-announces-positive-topline-results-0


FINANCIAL:

$RGNX (+6%) - REGENXBIO ANNOUNCES AGREEMENT TO MONETIZE PORTION OF ZOLGENSMA® ROYALTIES FOR $200 MILLION

http://ir.regenxbio.com/news-releases/news-release-details/regenxbio-announces-agreement-monetize-portion-zolgensmar


0 comments